.
AXP financial statements
* Numbers in millions
Year |
2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | TTM |
---|---|---|---|---|---|---|---|---|---|---|---|
Capitalization * |
6 041 | 13 241 | 23 229 | 32 588 | 29 485 | 26 768 | 22 448 | 22 992 | 21 624 | 28 098 | 33 873 |
EV * |
5 501 | 12 400 | 22 812 | 31 701 | 31 932 | 28 857 | 24 752 | 24 472 | 21 440 | 27 695 | 27 695 |
Stock price € |
32.97 | 69.52 | 118.8 | 164.5 | 138.15 | 119.5 | 100.26 | 103.24 | 96.88 | 127.66 | 153.9 |
Number of shares * |
183 | 190 | 196 | 198 | 213 | 224 | 224 | 223 | 223 | 220 | 220 |
EPS |
0,96 | 1,34 | 1,29 | 3,32 | 0,68 | 1,78 | 1,98 | 0,35 | 10,77 | 2,74 | 2,74 |
Revenue * |
783 | 1 134 | 1 551 | 2 234 | 2 604 | 3 084 | 3 551 | 4 131 | 4 991 | 6 070 | 6 070 |
Net income * |
175 | 255 | 253 | 657 | 144 | 399 | 443 | 78 | 2 404 | 603 | 603 |
Operating profit * |
244 | 453 | 567 | 916 | 682 | 793 | 804 | 1 595 | 2 140 | 2 860 | 2 860 |
Total liabilities * |
260 | 643 | 936 | 900 | 4 875 | 4 559 | 4 690 | 4 767 | 6 273 | 6 452 | 6 452 |
Net debt * |
-539 | -841 | -417 | -886 | 2 446 | 2 089 | 2 304 | 1 480 | -184 | -403 | -403 |
Total assets * |
1 395 | 2 614 | 3 318 | 4 202 | 13 133 | 13 253 | 13 583 | 13 932 | 17 545 | 18 103 | 18 103 |
Equity * |
1 134 | 1 971 | 2 382 | 3 302 | 8 259 | 8 694 | 8 893 | 9 165 | 11 272 | 11 651 | 11 651 |
Cash and investments * |
541 | 990 | 1 515 | 1 962 | 1 385 | 1 293 | 1 474 | 1 564 | 2 750 | 2 999 | 2 999 |
Over the past 10 years, the maximum capitalization of Alexion Pharmaceuticals, Inc. is 32 588, the minimum is 6 041. Maximum net income 2 404, Minimum net income 78. The maximum price of AXP shares is 164.5, the minimum price is 32.97.
.
AXP valuation
Year |
2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | TTM |
---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
34,46 | 51,96 | 91,85 | 49,61 | 204,21 | 67,09 | 50,64 | 296,28 | 8,99 | 46,57 | 56,14 |
P/B |
5,32 | 6,72 | 9,75 | 9,87 | 3,57 | 3,08 | 2,52 | 2,51 | 1,92 | 2,41 | 2,91 |
P/S |
7,71 | 11,68 | 14,97 | 14,59 | 11,32 | 8,68 | 6,32 | 5,57 | 4,33 | 4,63 | 5,58 |
E/P |
3% | 2% | 1% | 2% | 0% | 1% | 2% | 0% | 11% | 2% | 2% |
P/FCF |
24,35 | 34,06 | 49,63 | 64,73 | 75,82 | 35,55 | 29,60 | 107,94 | 11,30 | 9,70 | 11,70 |
.
AXP profitability
Year |
2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | TTM |
---|---|---|---|---|---|---|---|---|---|---|---|
ROE |
15% | 13% | 11% | 20% | 2% | 5% | 5% | 1% | 21% | 5% | |
ROA |
14% | 15% | 10% | 20% | 4% | 10% | 10% | 1% | 26% | 6% | |
ROIC |
21% | 20% | 21% | 25% | 6% | 6% | 6% | 13% | 13% | 17% |